Video

Dr. Burtness on the Head and Neck Symposium Design

Author(s):

Barbara Burtness, MD

In Partnership With:

Dr. Barbara Burtness from Fox Chase Cancer Center on the Head and Neck Symposium Design

Barbara Burtness, MD, Chief, head and neck medical oncology, co-leader, developmental therapeutics, Fox Chase Cancer Center, discusses how the 7th Annual Multidisciplinary Symposium on Head and Neck Cancer was designed around the unique nature of head and neck cancer.

The radiation, surgical, and medical oncologist will evaluate each patient treated for head and neck cancer. The speakers, topics, and those in attendance will represent these multiple disciplines.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Jay M. Short, PhD, chairman, chief executive officer and co-founder of BioAtla
July 23rd 2024

FDA Grants Fast Track Designation to Ozuriftamab Vedotin in Recurrent/Metastatic HNSCC

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Kedar Kirtane, MD
July 18th 2024

Autologous TIL Therapy Plus Pembrolizumab Under Exploration in PD-L1–Resistant Advanced HNSCC

USC Norris Comprehensive Cancer Center, UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center, Fox Chase Cancer Center, the University of Chicago Comprehensive Cancer Center
May 1st 2023

Stand Up to Cancer Grant Recipients Discuss Initiative to Expand Access to Early-Phase Clinical Trials

Nikita Dahake, MD
July 13th 2024

Temple University Hospital and Fox Chase Cancer Center Researchers Characterize HER2 Mutations in Patients With Lung Adenocarcinoma

Robert Metcalf, MBChB, MRCP, PhD, of Christie National Health Service Foundation Trust
July 11th 2024

First-line Eftilagimod Alpha Plus Pembrolizumab Generates Favorable ORR in PD-L1–Negative HNSCC